Alopecia areata

Alopecia areata is a common autoimmune condition in which the immune system, which is supposed to attack invaders, mistakes the hair follicle for the enemy and shuts it down. The result is sudden, smooth, round, coin-shaped bald patches, usually on the scalp but possible anywhere there is hair. Around 2% of people experience it at some point.¹

What it looks like

The patches are strikingly clean-edged — bare skin, no scaling or scarring — which is part of how it is recognised. At the advancing edge, doctors look for “exclamation mark” hairs: short, broken stubs that taper to a narrower point at the scalp, like a tiny exclamation point standing in the bald zone.¹

Crucially, the follicles are shut down, not destroyed. That is the good news buried in the condition: because the follicle survives, hair can return.

What’s actually going on: a case of mistaken identity

Here is the genuinely interesting part. The hair follicle is one of a handful of places in the body that enjoys immune privilege — a kind of diplomatic immunity. It normally keeps a low profile by displaying very little of the molecular “ID badge” (MHC class I) that the immune system inspects, so patrolling immune cells leave it alone.

In alopecia areata, that immune privilege collapses. The follicle starts displaying its ID badges, the immune system reads its proteins as foreign, and a swarm of CD8+ T cells (the cytotoxic, search-and-destroy kind) gathers around the hair bulb — a pattern pathologists have long described as looking like a “swarm of bees.”¹

The attack runs on a self-reinforcing chemical loop. The T cells pour out interferon-gamma (IFN-γ); the besieged follicle responds by producing interleukin-15 (IL-15); and IL-15 whips the T cells into producing yet more IFN-γ. Both signals are relayed inside the cells by a family of enzymes called JAK (Janus kinases). A landmark 2014 study showed this loop driving the disease in mice — and, critically, that blocking JAK could switch the attack off and regrow the hair.² That single insight is the reason the modern drugs exist.

Is it in the genes? (mostly yes)

Alopecia areata runs in families, and the genetics are substantial: studies estimate that roughly 30–44% of the risk is explained by common gene variants, with identical twins far more likely to share the condition than fraternal ones.¹

A large genome-wide study found the culprit regions are almost all immune-system genes — the HLA region (the body’s ID-badge system), plus genes that control regulatory T cells (the immune system’s brakes), such as CTLA4 and the IL-2/IL-21 region. Tellingly, it also flagged genes for the very “stress signal” (an NKG2D ligand) that marks a follicle for destruction.³ In other words, the wiring for this particular friendly-fire incident is, to a real degree, inherited.

It travels with company

Because it is autoimmune, alopecia areata tends to keep company with other autoimmune and allergic conditions. Reviews report thyroid disease in roughly 8–28% of patients, vitiligo (patchy loss of skin pigment) in up to ~16%, and a strong overlap with atopic conditions like eczema, asthma, and hay fever.¹ None of these are guaranteed; they are simply more common than chance, which is why a new diagnosis often comes with a thyroid blood test.

So… is it stress?

This is the first question almost everyone asks, and it deserves a straight answer rather than a shrug. The honest summary: stress is a popular suspect, but it is not considered the cause, and the evidence that it triggers the disease is genuinely mixed.

A few things are well established. People with alopecia areata have markedly higher rates of anxiety and depression — one meta-analysis found roughly 2.5× the odds of anxiety and 2.7× the odds of depression compared with people without it.⁴ That is a real and important finding. But it is an association, not a direction: suddenly losing your hair in visible patches is itself distressing, so at least part of that arrow points the other way — the condition causing the stress, not the stress causing the condition.

What the science does not show is a clean, proven line from “stressful event” to “bald patch.” The disease is fundamentally autoimmune and genetic; a person essentially has to be predisposed for it to happen at all. Stress is plausible as a trigger or amplifier in someone already primed — there are believable nervous-system-to-immune-system pathways — but controlled studies have not nailed it down, and plenty of cases appear with no stressful trigger at all.¹

There is also a common mix-up worth clearing up, because it changes the answer. Stress is much more clearly linked to a different kind of hair loss: telogen effluvium, the diffuse, all-over shedding that shows up a couple of months after a shock and then grows back on its own. That is the “my hair fell out after a terrible year” story most people mean. Alopecia areata is the patchy, autoimmune one. If the loss is in smooth round coins, it is the areata kind; if it is a general thinning everywhere, the stress connection is on much firmer ground.

The practical upshot for anyone living with it: you almost certainly did not give this to yourself by being stressed, and a dermatologist — not folk wisdom — is the right guide to the options, which are now genuinely better than they have ever been.

A century of waiting, then a breakthrough

For most of medical history there was no reliable treatment — just steroids, patience, and wigs. That changed in June 2022, when the JAK inhibitor baricitinib became the first systemic drug ever approved specifically for severe alopecia areata, with a meaningful share of patients regrowing most of their scalp hair.⁵ A second drug, ritlecitinib, followed in 2023 and was the first approved down to age 12.⁶ Both work by jamming exactly the JAK relay described above — the lab insight from 2014, arriving in the pharmacy.

Public awareness of the condition also jumped in 2022, at the Academy Awards. Presenter Chris Rock made a joke about actress Jada Pinkett Smith’s shaved head — she had spoken publicly about living with alopecia areata — and her husband, Will Smith, walked on stage and slapped him. The moment dominated headlines for weeks and sent a great many people searching for what alopecia areata actually is.⁷ Proof that even a quiet autoimmune condition can end up, abruptly, in the headlines.

See also

• Alopecia (the umbrella term)
• Telogen effluvium (the stress-linked, reversible kind)
• Why hair turns gray
• Keratin

References

1. Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. “Alopecia areata.” Nature Reviews Disease Primers 3, 17011 (2017). DOI 10.1038/nrdp.2017.11. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

2. Xing L, Dai Z, Jabbari A, et al. “Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.” Nature Medicine 20, 1043–1049 (2014). DOI 10.1038/nm.3645. ↩

3. Petukhova L, Duvic M, Hordinsky M, et al. “Genome-wide association study in alopecia areata implicates both innate and adaptive immunity.” Nature 466, 113–117 (2010). DOI 10.1038/nature09114. ↩

4. Okhovat J-P, Marks DH, Manatis-Lornell A, Hagigeorges D, Locascio JJ, Senna MM. “Association between alopecia areata, anxiety, and depression: A systematic review and meta-analysis.” Journal of the American Academy of Dermatology (2019). PubMed 31163237. ↩

5. King B, Ohyama M, Kwon O, et al. (BRAVE-AA Investigators). “Two Phase 3 Trials of Baricitinib for Alopecia Areata.” New England Journal of Medicine 386(18), 1687–1699 (2022). DOI 10.1056/NEJMoa2110343. Baricitinib (Olumiant) was FDA-approved for severe alopecia areata on 13 June 2022. ↩

6. “FDA approves second Yale-researched treatment for alopecia areata.” Yale News, 26 June 2023. news.yale.edu. (Ritlecitinib, brand name Litfulo, for ages 12 and up.) ↩

7. “What’s behind the slap Will Smith gave Chris Rock at the Oscars.” NPR, 28 March 2022. npr.org. (Jada Pinkett Smith has spoken publicly about living with alopecia areata.) ↩